Inventor · disambiguated record
Mark Sleeman
Also filed as: SLEEMAN MARK · SLEEMAN MARK CHRISTOPHER · SLEEMAN MARK W
26 granted patents·21 pending applications·715 citations·filing 1999–2025
97Inventor score
Top patents by PatentIndex Score
47 records- 0198US9550837B2Therapeutic uses of anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2015·Granted Jan 24, 2017·31 cites·10 claims
- 0298US9018356B2Anti-ANGPTL3 antibodies and uses thereofSLEEMAN MARK W·Filed 2012·Granted Apr 28, 2015·86 cites·12 claims
- 0398US8501184B2High affinity human antibodies to PCSK9SLEEMAN MARK W·Filed 2010·Granted Aug 6, 2013·76 cites·3 claims
- 0498US8357371B2Methods for treating hypercholesterolemia using antibodies to PCSK9REGENERON PHARMA·Filed 2011·Granted Jan 22, 2013·89 cites·16 claims
- 0598US8062640B2High affinity human antibodies to PCSK9SLEEMAN MARK W·Filed 2009·Granted Nov 22, 2011·237 cites·3 claims
- 0696US12269897B2Anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2023·Granted Apr 8, 2025·1 cites·12 claims
- 0796US10941210B2Anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2018·Granted Mar 9, 2021·6 cites·8 claims
- 0896US10023654B2Anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2016·Granted Jul 17, 2018·16 cites·18 claims
- 0995US9587029B2Human antibodies to the glucagon receptor and methods of use thereofREGENERON PHARMA·Filed 2015·Granted Mar 7, 2017·15 cites·19 claims
- 1095US7378095B2Methods of treating type I diabetes by blocking VEGF-mediated activityREGENERON PHARMA·Filed 2005·Granted May 27, 2008·24 cites·5 claims
- 1194US9724411B2Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9REGENERON PHARMA·Filed 2013·Granted Aug 8, 2017·15 cites·32 claims
- 1294US9127068B2Nucleic acids encoding human glucagon receptor antibodiesREGENERON PHARMA·Filed 2013·Granted Sep 8, 2015·20 cites·10 claims
- 1394US8545847B2Human antibodies to the human glucagon receptor and methods of use thereofOKAMOTO HARUKA·Filed 2011·Granted Oct 1, 2013·32 cites·17 claims
- 1491US9951127B2Anti-ANGPTL3 antibodies and uses thereofREGENERON PHARMA·Filed 2015·Granted Apr 24, 2018·7 cites·5 claims
- 1590US2025136675A1Anti-angptl3 antibodies and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1689US7052691B2Methods of treating diabetes by blocking VEGF-mediated activityREGENERON PHARMA·Filed 2004·Granted May 30, 2006·32 cites·13 claims
- 1788US10233250B2Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levelsREGENERON PHARMA·Filed 2017·Granted Mar 19, 2019·4 cites·21 claims
- 1888US9120851B2Human antibodies to human angiopoietin-like protein 4REGENERON PHARMA·Filed 2012·Granted Sep 1, 2015·11 cites·11 claims
- 1985US12269889B2Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levelsREGENERON PHARMA·Filed 2022·Granted Apr 8, 2025·0 cites·20 claims
- 2084US10358487B2Anti-ANGPTL3 antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Jul 23, 2019·2 cites·10 claims
- 2183US2022403016A1Anti-angptl3 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2281US8354103B2Human antibodies to human angiopoietin-like protein 4REGENERON PHARMA·Filed 2010·Granted Jan 15, 2013·5 cites·6 claims
- 2380US12441790B2Binding proteins to the human thrombin receptor, PAR4UNIV MONASH·Filed 2023·Granted Oct 14, 2025·0 cites·15 claims
- 2480US2025304704A1Human antibodies to the glucagon receptorREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2580US2022153825A1Anti-angptl3 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2679US2025154286A1Anti-pcsk9 antibodiesREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2777US2021253735A1Anti-pcsk9 antibodiesREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2877US2025075216A1Treatment Of Muscle Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2977US2025129366A1Treatment Of Liver Disease Or Metabolic Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3073US11498970B2Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levelsREGENERON PHARMA·Filed 2020·Granted Nov 15, 2022·0 cites·11 claims
- 3173US10640566B2Nucleic acid molecules encoding antibodies to the human glucagon receptorREGENERON PHARMA·Filed 2019·Granted May 5, 2020·0 cites·10 claims
- 3269US2019315851A1Anti-angptl3 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 3366US2025171516A1Peptide acids as a glp1r agonist and antibody-drug conjugates thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3465US2024199728A1Methods of treating obesity, diabetes, and liver dysfunctionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3564US2013085266A1ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICSREGENERON PHARMA·Filed 2012·Application pending·0 cites
- 3662US2013064834A1Methods for treating hypercholesterolemia using antibodies to pcsk9REGENERON PHARMA·Filed 2012·Application pending·0 cites
- 3761US11780915B2Binding proteins to the human thrombin receptor, PAR4UNIV MONASH·Filed 2018·Granted Oct 10, 2023·0 cites·20 claims
- 3859US12250931B2Genetically modified mouse with a humanized PNPLA3 gene and methods of useREGENERON PHARMA·Filed 2021·Granted Mar 18, 2025·0 cites·23 claims
- 3957US2017296657A1Methods for Treating Hypercholesterolemia and Reducing LDL-C Using Antibodies to PCSK9REGENERON PHARMA·Filed 2017·Application pending·0 cites
- 4056US2005096264A1Methods for treating obesity and related conditions with glycoprotein hormone beta family hormonesFiled 2004·Application pending·0 cites
- 4156US2005250185A1OGH fusion polypeptides and therapeutic uses thereofMURPHY ANDREW J·Filed 2004·Application pending·0 cites
- 4255US2004142868A1Method of treating liver steatosis in a mammalFiled 2004·Application pending·0 cites
- 4353US2004033954A1Therapeutic method for combined use of modified CNTF and thiadolidinedioneFiled 2003·Application pending·0 cites
- 4447US6680291B1Modified ciliary neurotrophic factor, method of making and methods of use thereofREGENERON PHARMA·Filed 1999·Granted Jan 20, 2004·6 cites·6 claims
- 4547US2004205831A1Transgenic SHIP2 animals and in vivo screening methodsFiled 2003·Application pending·0 cites
- 4638US2006058224A1Methods of treating obesity with combination therapeuticsYANCOPOULOS GEORGE D·Filed 2005·Application pending·0 cites
- 4734US2005070519A1Cyclisation process for the preparation of c-2 beta-lactam compoundsFiled 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →